T he optimal duration of dual antiplatelet therapy (DAPT) after coronary arterial stenting is an important question for clinicians and patients alike and represents a dynamic state of benefit and risk to achieve optimal outcomes. Clinicians must carefully balance the risk for future coronary arteryrelated events with an assessment of bleeding risk and, in many instances, recognize a changing risk-benefit relationship from the time of stent implantation. Patients must work closely with their healthcare providers to understand their medical condition-the basis for and importance of the treatments recommended-and to openly share their values, preferences, and anticipated obstacles to adhering to medical advice, including cost and limited access to ambulatory clinics in the community. The debate over duration of therapy comes at a time when national health care is facing serious challenges, with costs to individual patients contributing to an increasing divide among social classes in the United States and abroad.
"Things are not always as simple as they first appear."
Phaedrus, 25 ad 1 T he optimal duration of dual antiplatelet therapy (DAPT) after coronary arterial stenting is an important question for clinicians and patients alike and represents a dynamic state of benefit and risk to achieve optimal outcomes. Clinicians must carefully balance the risk for future coronary arteryrelated events with an assessment of bleeding risk and, in many instances, recognize a changing risk-benefit relationship from the time of stent implantation. Patients must work closely with their healthcare providers to understand their medical condition-the basis for and importance of the treatments recommended-and to openly share their values, preferences, and anticipated obstacles to adhering to medical advice, including cost and limited access to ambulatory clinics in the community. The debate over duration of therapy comes at a time when national health care is facing serious challenges, with costs to individual patients contributing to an increasing divide among social classes in the United States and abroad. 2 It also presents an opportunity to honor a pragmatic side of precision medicine as a priority for population health and the scientific community. 3 
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To arrive at our position that not all patients undergoing coronary arterial stent implantation require at least 12 months of DAPT, we posed the following questions: What is the goal of DAPT following stent implantation; what is the evidence in favor of either <12 or >12 months of DAPT after stent implantation; what are the underlying determinants of benefit and risk for DAPT; what are the most common factors that affect the duration of DAPT in clinical practice; and who are the optimal candidates for <12 months of DAPT?
What Is the Goal of DAPT After
Stent Implantation?
As with other blood-contacting medical devices, thrombosis is the predominant cause of failure after stent implantation. Accordingly, the goal of antithrombotic therapy in general and DAPT in particular is to reduce the risk of cardiovascular events, including stent thrombosis (ST), 4, 5 a life-threatening emergency. This is particularly important in the early time period 6,7 after procedure-related vascular injury and before strut endothelialization 8 when ST is most likely to occur. 9, 10 Prevention of ischemic and thrombotic events outside of or at a distance from the stented site is also a potential goal of therapy, particularly over the ensuing weeks and months.
What Is the Evidence in Favor of
Either <12 or >12 Months of DAPT After Stent Implantation?
Shorter Is Sufficient
The optimal duration of DAPT after drug-eluting stent (DES) implantation was the basis of a recent systematic review and meta-analysis performed by Giustino and colleagues. 12 Ten randomized trials and 32 135 patients were included in the analysis (Table 1) . Short-duration DAPT, by definition 3, 6, or 12 months after the procedure, compared with long-duration DAPT, defined as 18 to 30 months after stent implantation, had a higher rate of definite or probable ST (odds ratio, 1.71; 95% confidence interval [CI], 1.26-2.32; P=0.001), particularly among patients with first-generation DES compared with those with second-generation DES (odds ratio, 3.94; 95% CI, 2.20-7.05; P int =0.008; Figure 1 and Table 2 ). Trials of 3-or 6-month DAPT discontinuation predominantly (≈75%) included patients who had received second-generation DES. In contrast, ≥12-month DAPT discontinuation trials had, on average, 50% second-generation DES. Short-term DAPT was associated with a significantly lower risk of clinically significant bleeding (odds ratio, 0.63; 95% CI, 0.52-0.75; P=0.001) and a numerically lower all-cause mortality rate (odds ratio, 0.87; 95% CI, 0.74-1.01; P=0.073). When the available data are considered collectively, for every ST event averted with long-duration DAPT, there would be 2.1 clinically significant bleeding events. 9, 11, [13] [14] [15] [16] [17] [18] [19] [20] 
Longer May Be Better
The DAPT Trial 11 identified 25 682 patients who had undergone stent implantation. From the original cohort, 22 866 patients received DES and were followed up while receiving open-label DAPT for 12 months. At 12 months, patients who had not experienced a major adverse cardiovascular or cerebrovascular event, repeat revascularization, or either moderate or severe bleeding and had been adherent to thienopyridine therapy without interruption for >14 days were eligible for randomization (n=9961 or 38% of the original cohort). In this selected group of patients, continued treatment up to 30 months with a thienopyridine compared with aspirin monotherapy reduced the rates of ST Figure 2 ). Stent-related thrombus consists of platelets and fibrin. Artificial or nonbiological surfaces that currently typify all blood-contact medical devices promote clotting in a series of well-orchestrated events. These include protein adsorption; adhesion of platelets, erythrocytes, and leukocytes; and thrombin generation. The local concentration of proteins, including coagulation factors, can exceed plasma concentrations by 1000-fold, facilitating proteinprotein and cell-cell interactions and driving the biochemical reactions needed for coagulation. 25 The available evidence from animal models and large human studies strongly supports a requirement for platelet inhibition to minimize the risk of ST. [26] [27] [28] On the basis of histological samples, polymer-based DES impair arterial healing, with a lack of endothelial cell confluence and persistence of fibrin strands at deployment sites, particularly with paclitaxel first-generation DES [29] [30] [31] [32] ( Figure 3 ). This property is particularly evident in areas of penetration of the necrotic core of plaque, malapposition with the vessel wall, inadequate stent deployment, overlapping stents, excessive stent length, and thicker stent struts and at bifurcation lesions. 33 Hypersensitivity reactions have been reported but are an uncommon contributor to ST.
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Risk
DAPT as a treatment strategy, whether used in patients with or in those without stents, is associated with a widely recognized and well-documented increased risk for major bleeding, with reported rates up to 3.7% within the initial 30 days 35 and lifethreatening bleeding approaching 3.0%. 36 Unlike the absolute risk of ST, the risk for bleeding is not limited primarily to the early phase of treatment. The Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE) study randomized 12 562 patients to aspirin or DAPT. 37, 38 Bleeding rates were significantly higher among patients receiving DAPT compared with those given aspirin alone. This heightened risk was evident throughout the duration of the trial. Similarly, the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial randomized 15 603 patients with either documented atherosclerotic disease or multiple risk factors to DAPT or aspirin monotherapy, with a follow-up period of 28 months. Although a benefit for ischemic and thrombotic outcomes was not observed, there was a clear signal for heightened bleeding with DAPT. 39, 40 Cox proportional hazard models were used in a separate analysis to evaluate correlates of moderate or severe bleeding with the time to a first bleeding event. 40 The risk of bleeding was greatest in the first year of therapy in both treatment groups. There were twice as many patients in the DAPT group who discontinued study drug because of moderate or severe bleeding. When patients without moderate or severe bleeding in the first year of therapy were selected, there was an 18% greater likelihood of bleeding in the subsequent 18 months of DAPT compared with placebo (HR, 1.18; 95% CI, 0.917-1.52; P=0.197). nearly 60% of all patients who discontinued study medication because of bleeding did so after the first year. Cardiovascular death, all-cause mortality, and MI occurred more frequently among patients with even moderate bleeding during the 30-month follow-up period. Large metaanalyses have corroborated the observations of individual clinical trials 41 ( Figure 4 ) and highlight the challenge clinicians face in accurately predicting when and in whom serious bleeding will occur. ‡The maximum length of follow-up was 24 months; however, the maximum duration of DAPT was 12 months. In the analyses, outcomes at 12 months have been included. §High-risk ACS is excluded. ║100% Endeavor zotarolimus-eluting stent in the 3-month group.
In the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to
Placebo on a Background of Aspirin (PEGASUS-TIMI 54) trial, 42 21 162 patients who experienced an MI 1 to 3 years previously received ticagrelor 90 mg twice daily, ticagrelor 60 mg twice daily, or placebo. All patients received aspirin 75 to 150 mg daily. More than 80% of patients had undergone prior percutaneous coronary intervention. At 3 years of follow-up, with two thirds of patients remaining on study drug, the composite end point of death, MI, or stroke occurred in 7.85%, 7.77%, and 9.04% of patients, respectively (HR for ticagrelor 90 mg versus placebo, 0.85; 95% CI, 0.75-0.96; P=0.008; HR for ticagrelor 60 mg versus placebo, 0.84; 95% CI, 0.74-0.95; P=0.004). The rates of Thrombolysis in Myocardial Infarction (TIMI) minor and major bleeding were significantly increased by 3-to 4-fold with ticagrelor; however, the rate of fatal bleeding did not differ between treatment groups. Intracranial hemorrhage was numerically higher among patients receiving ticagrelor and reached borderline statistical significance in those enrolled in the 90 mg twice daily group (HR, 1.44; 95% CI, 0.83-2.49; P=0. 19) .
Using a pairwise and Bayesian network meta-analysis of randomized trials (n=31 666 patients), Palmerini and colleagues 43 found that shorter-duration DAPT was associated with a significantly lower all-cause mortality compared with longer-duration DAPT (HR, 0.82; 95% CI, 0.69-0.98; P=0.02; number needed to treat=325). The lower mortality was attributable to reduced noncardiac causes (HR, 0.67; 95% CI, 0.51-0.89; P=0.006; number needed to treat=347). A shorter duration of DAPT was also associated with a lower risk of major bleeding but a higher risk of MI and ST. Increased allcause mortality was also observed in the DAPT trial among patients receiving 30 months of DAPT.
11 Considered collectively, the observations suggest that DAPT beyond 12 months reduces the risk of MI and ST, but it is associated with increased mortality that is not offset by reduced cardiac mortality.
It is important to understand the bleeding definitions used in DAPT duration trials: TIMI minor bleeding: Clinically overt, resulting in a hemoglobin drop of 3 to <5 g/dL.
TIMI major bleeding: Any intracranial hemorrhage; fatal bleeding; or overt bleeding with a >5-g/dL drop in hemoglobin. 44 BARC type IIIA: Overt bleeding plus a 3-to <5-g/dL drop in hemoglobin or any transfusion with overt bleeding.
BARC type IIIB: Overt bleeding plus a hemoglobin drop >5 g/dL; cardiac tamponade; bleeding requiring surgical intervention for control; or bleeding requiring vasopressors.
BARC type IIIC: Intracranial hemorrhage or intraocular bleed.
BARC type V: Fatal bleeding. 45 GUSTO moderate: Bleeding requiring blood transfusions but not associated with hemodynamic compromise.
GUSTO severe: Intracranial hemorrhage; bleeding associated with hemodynamic compromise requiring treatment. 46 The differences in clinically significant bleeding favor short-term over prolonged DAPT with a highly significant one-third reduction in events. 11 This observation is consistent across studies with no evidence or heterogeneity (P for heterogeneity=0.953). The incidence of patient discontinuation of DAPT after DES implantation ranges from 14% at 30 days to >80% beyond 1 year, even in the setting of rigorous follow-up offered in randomized, clinical trials. 47 In a pooled analysis of 5 Endeavor trials, including a total of 2032 patients who received zotarolimus-eluting stents, only 76% of patients were on DAPT at 6 months, 40% at 12 months, and 32% at 24 months after stent implantation. 48 In the CURE study, 46.2% of patients in the DAPT arm discontinued the study medication temporarily, and 21.1% discontinued the study medication permanently. 38 
Cost of Prolonged DAPT
The use of prolonged DAPT presents a financial burden to patients and healthcare systems regionally and nationally. 49, 50 This is not limited to the cost of the drug itself but also involves the costs of patient care after any bleeding complication, including hospitalization, procedures, office visits, and the indirect costs of lost wages and caregiver expenses. 51 Bleeding, even mild by current criteria, may prompt discontinuation of platelet-directed therapy, increasing the risk for future ischemic and thrombotic events. The average out-of-pocket costs in the United States of a 30-day supply of drugs currently included along with aspirin for a DAPT-based strategy are as follows: clopidogrel (Plavix), $239.00; generic clopidogrel, $58.00; prasugrel, $300.00; and ticagrelor, $313.00.
Clinical Circumstances
The cessation of DAPT after stent implantation and its associated risk were investigated prospectively in the Patterns of non-Adherence to Anti-Platelet Regimens in Stented Patients (PARIS) registry. 52 Patients were subcategorized for DAPT cessation as physician-recommended discontinuation, brief interruption (for surgery), or disruption (noncompliance or because of bleeding). A total of 5018 patients were included in the final study population. The rates of discontinuation, brief interruption, and disruption were 40.8%, 10.51%, and 14.4%, respectively. The overall 2-year major adverse cardiac event (composite of cardiac death, probable or definite ST, MI, or target lesion revascularization) rate was 11.5%, with a majority of events occurring while patients were still taking DAPT. The adjusted HR for major adverse cardiac events among patients with DAPT resulting from interruption was 1.41 (95% CI, 0.94-2.12; P=0.10) and from disruption was 1.50 (95% CI, 1.14-1.97; P=0.004). Patients with planned discontinuation had a lower risk for major adverse cardiac events than those who remained on DAPT (HR, 0.63; 95% CI, 0.46-0.86). The greatest overall risk was observed when discontinuation or disruption occurred with both versus 1 antiplatelet medication.
Landmark analyses of each cessation group showed that the risk of events was highest in the first 30 days of drug cessation. One important exception was among patients with DAPT disruption because of bleeding who remained at risk for major adverse cardiac events well beyond 30 days.
Who Are the Optimal Candidates for <12 Months of DAPT?
In the Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia (PRODIGY) trial, 53 a total of 1465 patients entered after an acute coronary syndrome, whereas 505 patients had stable coronary artery disease. Patients were randomized to either 6 or 24 months of DAPT. At 24 months, the composite of death, MI, or stroke did not differ between treatment duration groups. In contrast, prolonged DAPT was associated with a 75% increase in BARC class II, III, or V bleeding in patients with acute coronary syndrome (7.5% versus 4.1%; HR, 1.75; 95% CI, 1.11-2.74; P=0.015) and a 5-fold increase among patients with stable coronary artery disease (8.2% versus 1.6%; HR, 5.37; 95% CI, 1.84-15.74; P=0.002), with a number needed to harm of 15.1 patients. Overall, net adverse cardiovascular events, including both ischemic-thrombotic and hemorrhagic, were doubled among patients with stable coronary artery disease receiving 24 versus 6 months of DAPT (P int =0.024).
In a subgroup analysis from the DAPT trial, 54 patients with bare metal stents were compared to determine the benefits and risks of 12 versus 30 months of DAPT. Among 1687 patients with bare metal stents, the rates of ST for prolonged versus shorter therapy were 0.5% versus 1.11% (HR, 0.49; 95% CI, 0.15-1.64; P=0.24), rates of major cardiovascular and cerebrovascular events were 4.04% versus 4.69% (HR, 0.92; P=0.72), and rates of moderate to severe bleeding were 2.03% versus 0.9% (n=16 versus 7; P=0.07), respectively. Thus, continued therapy with DAPT beyond 12 months increased bleeding risk without a reduction of ischemic-thrombotic events.
Finally, patients in whom the risk for moderate to severe bleeding outweighs the anticipated benefit should be considered candidates for <12 months of DAPT after stent implantation.
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Conclusions
The medical and scientific communities have put forward substantial and highly laudatory efforts to develop therapies that serve patients with coronary artery disease. We believe, and the existing data support, that DAPT for 12 months is not required in all patients after coronary artery stent implantation. Practicing clinicians must consider ischemic and thrombotic risk, as well as potential barriers to medication compliance, including costs in the current healthcare environment. They must also carefully assess bleeding risk in each patient before percutaneous coronary intervention and longitudinally to optimize outcomes.
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